Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.89 and traded as high as $3.32. Acasti Pharma shares last traded at $3.29, with a volume of 19,316 shares trading hands.
Acasti Pharma Trading Up 1.0 %
The company’s 50-day simple moving average is $2.95 and its 200 day simple moving average is $2.89. The stock has a market cap of $30.95 million, a P/E ratio of -0.65 and a beta of 1.61.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Read More
- Five stocks we like better than Acasti Pharma
- What is a SEC Filing?
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
